High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients

Irene Prediletto(University of Bern), Thomas Pabst(University Hospital of Bern), Thilo Zander(Luzerner Kantonsspital), Rachel Brégy(University of Bern), Ulrike Bacher(Hattiesburg Clinic), Urban Novak(University of Bern), Thomas Egger(Solothurner Spitäler), Behrouz Mansouri Taleghani(University of Bern), Daniel Betticher, Sarah A. Farag(University of Bern), Barbara Jeker(University of Bern)
Bone Marrow Transplantation
March 19, 2019
10.1038/s41409-019-0508-2
Cited by 20

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients
|Blood|2007|410
Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
|The Lancet|2015|392
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer
|British Journal of Cancer|1996|220
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
|Blood|2010|189